

## Synthesis of tryptophan *N*-glucoside

Melanie Schnabel, Birgit Römpp, Daniel Ruckdeschel and Carlo Unverzagt\*

*Bioorganische Chemie, Gebäude NWI, Universität Bayreuth, 95440 Bayreuth, Germany*

Received 3 September 2003; revised 22 October 2003; accepted 29 October 2003

This work is dedicated to Prof. W. Steglich on the occasion of his 70th birthday

**Abstract**—The naturally occurring L-tryptophan *N*-glucoside was synthesized using 2-*O*-pivaloylated glucosyl trichloroacetimidate, which gave  $\beta$ -*N*<sup>ln</sup>-glucosides. From 2-*O*-acetylated donors only tryptophan-1-yl-ethylidene compounds (amide acetals) were obtained. The employment of  $\alpha$ -azido L-tryptophan benzyl ester facilitated purification and deprotection and improved the yields of the glycosylation step.

© 2003 Elsevier Ltd. All rights reserved.

The amino acid tryptophan shows many biological functions. Tryptophan and its derivatives are of great interest due to their complex metabolism involving important metabolites and related diseases.<sup>1</sup> Besides the many examples of known tryptophan-containing natural products, a growing number of recently discovered C or N-linked tryptophan glycoconjugates has attracted interest. The C-mannosyl-L-tryptophan **1**<sup>2a,b</sup> was initially discovered in human RNase and several glycoproteins of the complement system.<sup>2c</sup> Fruits and other foods were found to be the source of *glyco*-tetrahydro- $\beta$ -carboline-3-carboxylic acids and various L-tryptophan-*N*-glycosides with pentoses as the sugar part.<sup>3</sup> L-Tryptophan *N*-glucoside **2**<sup>4a</sup> (Fig. 1) was previously discovered as a novel tryptophan metabolite in fruits and foods formed by an enzymatic process.<sup>4b</sup> The *N*-acylated derivative **3** was isolated from the flowers of *Pueraria Lobata*, a drug used in traditional Chinese medicine.<sup>5</sup>

There are only a few examples of synthetic tryptophan *N*-glycosides. In 1985 an *N*-glucosylated *N* <sup>$\alpha$</sup> -acetyl-D,L-tryptophan was obtained from *N* <sup>$\alpha$</sup> -acetyl-L-tryptophan and glucose in low yield.<sup>6</sup> Herderich et al. found analytical amounts of *N*- and C-glycosylated tryptophan derivatives among *glyco*-tetrahydro- $\beta$ -carbolines in acid-catalyzed condensations between pentoses<sup>3</sup> or


hexoses<sup>4a</sup> and tryptophan. Cyclic peptides have been reported to react at the indole nitrogen of tryptophan using either a glycal<sup>7a</sup> or a galactosyl bromide.<sup>7b</sup> *N*-Glycosyl-indoles have been obtained via the glycosylation of substituted indoles<sup>8a,b</sup> or indolines followed by oxidation to the corresponding *N*-glycosyl-indole.<sup>9</sup>

We report a chemical synthesis for tryptophan *N*-glucoside **2** suitable for preparing the amounts required for biological studies. Initially, we envisioned the formation of the  $\beta$ -linked tryptophan-*N*-glucoside from tetra-acetyl-glucosylimidate **4** and Cbz-Trp-OBzl **5**.<sup>10</sup> The glycosylation was initiated with boron trifluoride etherate as an activator and led to the unexpected tryptophan amide acetal **7**, which can be viewed as an aza analogue of a glycosyl orthoester (Fig. 2). Only one stereoisomer was found, which was arbitrarily assigned. The isolation of stable indole-1-yl-ethylidene glycosides has been reported in the literature.<sup>8</sup> To determine if the formation of orthoester-like indolyl glycosides was related to the protecting groups of the amino acid moiety, the azido-protected tryptophan **6** was employed. This compound was synthesized from tryptophan benzyl ester<sup>10a</sup> in 68% yield following a procedure introduced by Vasella et al.<sup>11</sup> However, even in the presence of the strong activator TMSOTf the reaction of the azide **6** with donor **4** only gave amide acetal **8**,<sup>12</sup> suggesting a low tendency for this compound to rearrange to the desired *N*-glycoside.


To avoid the formation of the orthoester-like compounds, replacement of the 2-acetyl moiety of donor **4**

**Keywords:** Tryptophan *N*-glucoside; Tryptophan; Glycosylation.

\* Corresponding author. Tel.: +49-921-552670; fax: +49-921-555365; e-mail: [carlo.unverzagt@uni-bayreuth.de](mailto:carlo.unverzagt@uni-bayreuth.de)



**Figure 1.** Structures of tryptophan C-mannoside **1** and tryptophan N-glucosides **2** and **3**.



**Figure 2.** Reagents and conditions: (a) **4** + **5**, 0.14 equiv BF<sub>3</sub>·Et<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 42%; (b) **4**+**6**, 0.1 equiv TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, –10 °C, 26%.


with the bulky 2-pivaloyl residue as introduced by Kunz and Harreus<sup>13</sup> was planned. This protecting group has been described as giving N-glycosylated indoles.<sup>8b</sup>

The required trichloroacetimidate building block **11** (Fig. 3) was synthesized from tetra-acetyl-glucose **9**.<sup>14</sup> After pivaloylation of OH-2 the anomeric acetate was cleaved with hydrazine acetate and the intermediate hemiacetal was converted to the imidate **11** in a DBU-catalyzed reaction with trichloroacetonitrile,<sup>15</sup> giving an overall yield of 78% over the two steps.

The glycosylation of tryptophan derivative **5** with the pivaloylated donor **11** activated by boron trifluoride

etherate gave the desired tryptophanyl-N-glucoside **12** in 17% yield (Fig. 3). Using TMSOTf as an activator gave better yields (27%) but in both cases the product **12** could not be purified completely by flash chromatography. Thus, the  $\alpha$ -azido-tryptophan-benzyl ester **6** was examined as an acceptor. The reaction of azide **6**, glycosyl donor **11** and boron trifluoride etherate as an activator furnished the N-glycosylated tryptophan **13**,<sup>16</sup> which could easily be purified by flash chromatography (23% yield). When TMSOTf was used for activation the yield could be raised to 43%.

The deprotection of tryptophan N-glucoside **13** was accomplished via a two step procedure. Catalytic



**Figure 3.** Reagents and conditions: (a) 5 equiv PivCl, py, CHCl<sub>3</sub>, rt, 91%; (b) (i) 1.5 equiv H<sub>2</sub>N–NH<sub>3</sub>OAc, DMF, rt; (ii) 0.1 equiv DBU, 5 equiv CCl<sub>3</sub>CN, 0 °C, 78% (over two steps); (c) 1.2 equiv BF<sub>3</sub>·Et<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, –10 °C, 17%; (d) 0.1 equiv TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, –10 °C, 27%; (e) 0.6 equiv BF<sub>3</sub>·Et<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, –10 °C, 23%; (f) 0.1 equiv TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, –15 °C, 43%; (g) PdO–H<sub>2</sub>O, H<sub>2</sub>, MeOH, rt, 42%; (h) MeNH<sub>2</sub> 40% in H<sub>2</sub>O, rt, 77%.

hydrogenation over palladium oxide-hydrate removed the benzyl ester and reduced the azido group simultaneously. Subsequently, complete deacetylation was carried out with 40% aqueous methylamine.<sup>17</sup> After purification using size exclusion chromatography (Superdex 30) the target molecule **2** was obtained in 77% yield. NMR spectra were recorded in the same solvent as reported in the literature and showed excellent accordance.<sup>4a,18</sup> In conjunction with the optical rotation the structural assignment of the isolated compound was confirmed by total synthesis.

In conclusion we have developed a strategy to obtain the natural product *N*-glucosyl-tryptophan **2** by chemical synthesis. Key steps involve the introduction of a 2-pivaloyl moiety to suppress the formation of the tryptophan-1-yl amide acetals and the use of an  $\alpha$ -azido tryptophan derivative for improved yields. This chemical synthesis can provide sufficient amounts of *N*-glucosyl-tryptophan to conduct biological studies.

### Acknowledgements

We are grateful to Degussa AG for a generous donation of chemicals.

### References and Notes

- Sainio, E. L.; Pulkki, K.; Young, S. N. *Amino Acids* **1996**, *10*, 21–47.
- (a) Hofsteenge, J.; Müller, D. R.; de Beer, T.; Löffler, A.; Richter, W. J.; Vliegthart, J. F. G. *Biochemistry* **1994**, *33*, 13524–13530; (b) Gäde, G.; Kellner, R.; Rinehart, K. L.; Proefke, M. L. *Biochem. Biophys. Res. Commun.* **1992**, *189*, 1303–1309; (c) Hofsteenge, J.; Blommers, M.; Hess, D.; Furmanek, A.; Miroshnichenko, O. *J. Biol. Chem.* **1999**, *274*, 32786–32794.
- Diem, S.; Albert, J.; Herderich, M. *Eur. Food Res. Technol.* **2001**, *213*, 439–447.
- (a) Gutsche, B.; Grun, C.; Scheutzow, D.; Herderich, M. *Biochem. J.* **1999**, *343*, 11–19; (b) Diem, S.; Bergmann, J.; Herderich, M. *J. Agric. Food Chem.* **2000**, *48*, 4913–4917.
- Kinjo, J.-E.; Takeshita, T.; Nohara, T. *Chem. Pharm. Bull.* **1988**, *36*, 4171–4173.
- Nyhammar, T.; Pernemalm, P.-A. *Food Chem.* **1985**, *17*, 289–296.
- (a) Kessler, H.; Michael, K.; Kottenhahn, M. *Liebigs Ann. Chem.* **1994**, 811–816; (b) Itazaki, H.; Fujiwara, T.; Sato, A.; Kawamaru, Y.; Matsumoto, K. 1995, JP7109299; *Chem. Abstr.* **1995**, 701969.
- (a) Sokolova, T. N.; Shevchenko, V. E.; Preobrazhenskaya, M. N. *Carbohydr. Res.* **1980**, *83*, 249–261; (b) Buchanan, J. G.; Stoddart, J.; Wightman, R. H. *J. Chem. Soc., Perkin Trans. 1* **1994**, 1417–1426.
- Preobrazhenskaya, M. N.; Vigdorich, M. M.; Suvorov, N. N. *Tetrahedron* **1967**, *23*, 4653–4660, and references cited therein.
- (a) Arai, J.; Muramatsu, J. *J. Org. Chem.* **1983**, *48*, 121–123; (b) Guillaume, H. A.; Perich, J. W.; Johns, R. B.; Tregear, G. W. *J. Org. Chem.* **1989**, *54*, 1664–1668.
- Vasella, A.; Witzig, C.; Chiara, J.-L.; Martin-Lomas, M. *Helv. Chim. Acta* **1991**, *74*, 2073–2077.
- Compound **8**: ESI-MS: C<sub>32</sub>H<sub>34</sub>N<sub>4</sub>O<sub>11</sub> M<sub>r</sub> (calcd) 650.22, M (found) 673.18 (M+Na<sup>+</sup>); [ $\alpha$ ]<sub>D</sub><sup>21</sup> –1.1 (c 1.0, dichloromethane); <sup>1</sup>H NMR (360 MHz, [d<sub>6</sub>]-DMSO):  $\delta$  7.65 (d, J<sub>6,7</sub> = 8.2 Hz, 1H, H-7), 7.54 (d, J<sub>4,5</sub> = 7.8 Hz, 1H, H-4), 7.33–7.18 (m, 7H, Ph, H-2, H-6), 7.09 (dd, J<sub>4,5</sub> = 7.8 Hz, J<sub>5,6</sub> = 7.3 Hz, 1H, H-5), 5.78 (d, J<sub>1,2'</sub> = 5.7 Hz, 1H, H-1'), 5.14–5.10 (m, 3H, CH<sub>2</sub>-Ph, H-3'), 4.84–4.81 (m, 1H, H-4'), 4.63–4.59 (m, 1H, H- $\alpha$ ), 4.21–4.08 (m, 4H, H-2', H-5', H-6'), 3.18 (dd, J<sub>gem</sub> = 14.8 Hz, J<sub>vic</sub> = 5.7 Hz, 1H, H- $\beta$ a), 3.13 (dd, J<sub>gem</sub> = 14.8 Hz, J<sub>vic</sub> = 7.6 Hz, 1H, H- $\beta$ b), 2.10, 2.05, 1.97, 1.84 (4s, 12H, CH<sub>3</sub>); <sup>13</sup>C NMR (90 MHz, [d<sub>6</sub>]-DMSO):  $\delta$  170.2, 169.8, 169.5, 168.9 (4C=O), 135.3 (C<sub>q</sub>, Ph), 134.0 (C-7a), 129.1 (C-3a), 128.6–127.9 (CH, Ph), 124.1 (C-2), 122.3 (C-6), 119.9 (C-5), 118.7 (C-4), 112.4 (C'), 112.3 (C-7), 110.0 (C-3), 96.8 (C-1', J<sub>C,H</sub> = 186.7 Hz), 72.2 (C-2'), 68.9 (C-3'), 67.7 (C-4'), 66.8 (CH<sub>2</sub>-Ph), 66.5 (C-5'), 62.8 (C-6'), 61.3 (C- $\alpha$ ), 26.9 (C- $\beta$ ), 23.8 (CH<sub>3</sub>), 20.7, 20.6, 20.5 (CH<sub>3</sub>, OAc).
- Kunz, H.; Harreus, A. *Liebigs Ann. Chem.* **1982**, 41–48.
- Helferich, B.; Zirner, J. *Chem. Ber.* **1962**, *95*, 2604–2611.
- Schmidt, R. R.; Kinzy, W. *Adv. Carbohydr. Chem. Biochem.* **1994**, *50*, 21–123.
- Compound **13**: ESI-MS: C<sub>35</sub>H<sub>40</sub>N<sub>4</sub>O<sub>11</sub> M<sub>r</sub> (calcd) 692.27, M (found) 715.31 (M+Na<sup>+</sup>); [ $\alpha$ ]<sub>D</sub><sup>24</sup> –20.0 (c 0.4, dichloromethane); IR (KBr)  $\nu$  = 2108.6 cm<sup>-1</sup> azide; <sup>1</sup>H NMR (360 MHz, [d<sub>6</sub>]-DMSO):  $\delta$  7.63 (d, J<sub>6,7</sub> = 8.4 Hz, 1H, H-7), 7.53 (d, J<sub>4,5</sub> = 7.7 Hz, 1H, H-4), 7.40–7.32 (m, 5H, Ph), 7.27 (s, 1H, H-2), 7.19 (dd, J<sub>6,7</sub> = 8.4 Hz, J<sub>5,6</sub> = 7.6 Hz, 1H, H-6), 7.06 (dd, J<sub>4,5</sub> = 7.7 Hz, J<sub>5,6</sub> = 7.6 Hz, 1H, H-5), 6.22 (d, J<sub>1,2</sub> = 8.6 Hz, 1H, H-1'), 5.59–5.48 (m, 2H, H-2', H-3'), 5.25–5.15 (m, 3H, CH<sub>2</sub>-Ph, H-4'), 4.54–4.50 (m, 1H, H- $\alpha$ ), 4.33–4.29 (m, 1H, H-5'), 4.15–4.02 (m, 2H, H-6a', H-6b'), 3.18 (dd, J<sub>gem</sub> = 14.9 Hz, J<sub>vic</sub> = 5.2 Hz, 1H, H- $\beta$ a), 3.07 (dd, J<sub>gem</sub> = 14.9 Hz, J<sub>vic</sub> = 8.0 Hz, 1H, H- $\beta$ b), 2.04, 1.96, 1.93, (3 $\times$ s, total 9H, Ac), 0.67 (s, 9H, Piv); <sup>13</sup>C NMR (90 MHz, [d<sub>6</sub>]-DMSO):  $\delta$  175.5 (COOBz), 170.1, 169.7, 169.5, 169.4 (4CO), 136.3 (C-7a), 135.4 (C<sub>q</sub>, Ph), 128.5, 128.2, 128.1 (CH, Ph), 127.7 (C-3a), 124.2 (C-2), 122.1 (C-6), 120.0 (C-5), 118.7 (C-4), 110.8 (C-3), 110.4 (C-7), 81.1 (C-1'), 73.0 (C-5'), 72.5 (C-3'), 69.7 (C-2'), 68.0 (C-4'), 66.9 (CH<sub>2</sub>-Ph), 62.2 (C-6'), 61.5 (C- $\alpha$ ), 37.9 (C<sub>q</sub>, Piv), 26.6 (C- $\beta$ ), 26.1 (CH<sub>3</sub>, Piv), 20.5, 20.4, 20.1 (CH<sub>3</sub>, Ac).
- Griffin, B. E.; Jarman, M.; Reese, C. B. *Tetrahedron* **1968**, *24*, 639–662.
- Compound **2**: ESI-MS: C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub> M<sub>r</sub> (calcd) 366.1427, M (found) 367.1507 (M+H<sup>+</sup>); [ $\alpha$ ]<sub>D</sub><sup>21</sup> –19.0 (c 0.2, water); lit.<sup>4b</sup>: [ $\alpha$ ]<sub>D</sub><sup>25</sup> –20.3 (c 0.2, water); <sup>1</sup>H NMR (360 MHz, [d<sub>4</sub>]-MeOH+1% TFA):  $\delta$  7.62 (d, J<sub>4,5</sub> = 7.8 Hz, 1H, H-4), 7.58 (d, J<sub>6,7</sub> = 8.2 Hz, 1H, H-7), 7.36 (s, 1H, H-2), 7.23 (dd, J<sub>6,7</sub> = 8.2 Hz, J<sub>5,6</sub> = 7.1 Hz, 1H, H-6), 7.14 (dd, J<sub>4,5</sub> = 7.8 Hz, J<sub>5,6</sub> = 7.1 Hz, 1H, H-5), 5.51 (d, J<sub>1,2'</sub> = 9.1 Hz, 1H, H-1'), 4.28 (dd, J<sub>8a,9</sub> = 8.6 Hz, J<sub>8b,9</sub> = 4.5 Hz, 1H, H-9), 3.92–3.85 (m, 2H, H-2', H-6a'), 3.67–3.46 (m, 5H, H-3', H-4', H-5', H-6b', H-8a), 3.33–3.27 under MeOD signal (m, 1H, H-8b); <sup>13</sup>C NMR (90 MHz, [d<sub>4</sub>]-MeOH + 1% TFA):  $\delta$  171.5 (COOH), 138.8 (C-7a), 129.1 (C-3a), 125.7 (C-2), 123.6 (C-6), 121.3 (C-5), 119.3 (C-4), 111.1 (C-7), 109.6 (C-3), 86.4 (C-1'), 80.3 (C-5'), 78.6 (C-3'), 74.0 (C-2'), 71.2 (C-4'), 62.3 (C-6'), 54.1 (C-9), 27.3 (C-8).